EA201592006A1 - Новые биспецифические связывающие молекулы с противоопухолевой активностью - Google Patents
Новые биспецифические связывающие молекулы с противоопухолевой активностьюInfo
- Publication number
- EA201592006A1 EA201592006A1 EA201592006A EA201592006A EA201592006A1 EA 201592006 A1 EA201592006 A1 EA 201592006A1 EA 201592006 A EA201592006 A EA 201592006A EA 201592006 A EA201592006 A EA 201592006A EA 201592006 A1 EA201592006 A1 EA 201592006A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- amino acid
- seq
- bispecific binding
- binding molecules
- tumor activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13164555 | 2013-04-19 | ||
| PCT/EP2014/054390 WO2014170063A1 (en) | 2013-04-19 | 2014-03-06 | Novel bispecific binding molecules with antitumoral activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201592006A1 true EA201592006A1 (ru) | 2016-03-31 |
Family
ID=48128216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201592006A EA201592006A1 (ru) | 2013-04-19 | 2014-03-06 | Новые биспецифические связывающие молекулы с противоопухолевой активностью |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2986630B1 (https=) |
| JP (2) | JP6694808B2 (https=) |
| KR (1) | KR20160002882A (https=) |
| CN (1) | CN105189544A (https=) |
| AU (1) | AU2014256037B2 (https=) |
| BR (1) | BR112015026143A2 (https=) |
| CA (1) | CA2908988A1 (https=) |
| CL (1) | CL2015003085A1 (https=) |
| EA (1) | EA201592006A1 (https=) |
| HK (1) | HK1214605A1 (https=) |
| MX (1) | MX2015014608A (https=) |
| PH (1) | PH12015502278A1 (https=) |
| SG (1) | SG11201508231UA (https=) |
| WO (1) | WO2014170063A1 (https=) |
| ZA (1) | ZA201507752B (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| FI126633B (en) | 2015-07-10 | 2017-03-15 | Next Biomed Therapies Oy | Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1) |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| JP7784795B2 (ja) | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| US10722589B2 (en) * | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| CA3060190A1 (en) * | 2017-04-24 | 2018-11-01 | Ichnos Sciences SA | T cell redirecting bispecific antibodies for the treatment of egfr positive cancers |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR20200068647A (ko) | 2017-08-11 | 2020-06-15 | 시티 오브 호프 | 트랜스페린 수용체 (TfR)에 대한 RNA 앱타머 |
| US20200181264A1 (en) * | 2017-08-11 | 2020-06-11 | City Of Hope | Bispecific antigen-binding molecule |
| CN111356700A (zh) | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | 受约束的条件性活化的结合蛋白 |
| CN111315773A (zh) * | 2017-09-08 | 2020-06-19 | 马弗里克治疗公司 | 含有Fc区的条件性活化的结合部分 |
| US20190100587A1 (en) * | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
| IL325995A (en) | 2018-02-08 | 2026-03-01 | Genentech Inc | Bispecific antigen binding molecules and methods of use |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CA3164226A1 (en) | 2019-12-11 | 2021-06-17 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| EP4337330A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| US11958906B2 (en) | 2022-04-13 | 2024-04-16 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025221728A2 (en) | 2024-04-15 | 2025-10-23 | Janssen Biotech, Inc. | Ltbr binding molecules and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1892248A1 (en) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| MX2012002428A (es) * | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| WO2011116387A1 (en) * | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
| EP2576621B1 (en) * | 2010-05-27 | 2019-04-10 | Genmab A/S | Monoclonal antibodies against her2 |
-
2014
- 2014-03-06 WO PCT/EP2014/054390 patent/WO2014170063A1/en not_active Ceased
- 2014-03-06 BR BR112015026143A patent/BR112015026143A2/pt not_active IP Right Cessation
- 2014-03-06 MX MX2015014608A patent/MX2015014608A/es unknown
- 2014-03-06 EA EA201592006A patent/EA201592006A1/ru unknown
- 2014-03-06 CN CN201480022196.2A patent/CN105189544A/zh active Pending
- 2014-03-06 CA CA2908988A patent/CA2908988A1/en not_active Abandoned
- 2014-03-06 KR KR1020157031680A patent/KR20160002882A/ko not_active Withdrawn
- 2014-03-06 SG SG11201508231UA patent/SG11201508231UA/en unknown
- 2014-03-06 JP JP2016508054A patent/JP6694808B2/ja not_active Expired - Fee Related
- 2014-03-06 AU AU2014256037A patent/AU2014256037B2/en not_active Ceased
- 2014-03-06 HK HK16102370.8A patent/HK1214605A1/zh unknown
- 2014-03-06 EP EP14710220.6A patent/EP2986630B1/en active Active
-
2015
- 2015-09-30 PH PH12015502278A patent/PH12015502278A1/en unknown
- 2015-10-16 ZA ZA2015/07752A patent/ZA201507752B/en unknown
- 2015-10-19 CL CL2015003085A patent/CL2015003085A1/es unknown
-
2019
- 2019-01-30 JP JP2019013831A patent/JP2019106997A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019106997A (ja) | 2019-07-04 |
| EP2986630B1 (en) | 2018-08-15 |
| CL2015003085A1 (es) | 2016-06-03 |
| SG11201508231UA (en) | 2015-11-27 |
| BR112015026143A2 (pt) | 2017-10-17 |
| JP6694808B2 (ja) | 2020-05-20 |
| WO2014170063A1 (en) | 2014-10-23 |
| HK1214605A1 (zh) | 2016-07-29 |
| AU2014256037B2 (en) | 2017-09-21 |
| PH12015502278A1 (en) | 2016-02-01 |
| MX2015014608A (es) | 2016-03-03 |
| CN105189544A (zh) | 2015-12-23 |
| JP2016516789A (ja) | 2016-06-09 |
| AU2014256037A1 (en) | 2015-10-29 |
| CA2908988A1 (en) | 2014-10-23 |
| ZA201507752B (en) | 2017-03-29 |
| EP2986630A1 (en) | 2016-02-24 |
| KR20160002882A (ko) | 2016-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201592006A1 (ru) | Новые биспецифические связывающие молекулы с противоопухолевой активностью | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| CY1124944T1 (el) | Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων | |
| EA201400488A1 (ru) | Полипептидные конструкции и их применение | |
| PH12018500664A1 (en) | Anti-lag3 antibodies and uses thereof | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| MA44885B1 (fr) | Protéines de liaison bispécifiques et leurs utilisations | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| MX2018003410A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| MX2024010987A (es) | Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control. | |
| EA201790934A1 (ru) | ВАРИАНТЫ ИНТЕРФЕРОНА α2b | |
| EA201791393A3 (ru) | Антитела к erbb3 и их применение | |
| MX2016004579A (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| MX2021000155A (es) | Moleculas de proteina multifuncionales que comprenden decorina y su uso. | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| MX2016008520A (es) | Anticuerpo bdca-2 antihumano novedoso. | |
| MX2021001418A (es) | Produccion de proteinas heteromultimericas usando celulas de mamifero. | |
| MY196874A (en) | Humanized anti-basigin antibodies and the use thereof | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| EA201790437A1 (ru) | Антигенсвязывающие белки, связывающиеся с cxcr3 | |
| MX393714B (es) | Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo. | |
| EP3974443A3 (en) | Peptides derived from melanoma-associated antigen b2 (mageb2) | |
| AR111767A1 (es) | Proteínas de unión al antígeno anti-jagged1 | |
| AR082160A1 (es) | Anticuerpos monoclonales dirigidos contra la toxina tetanica |